Clinical Research Online Journals|OMICS International|Journal Of Clinical Research And Bioethics

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Clinical Research Online Journals

OMICS Group International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS Group hosts over 700+ peer-reviewed journals and organizes over 3000+ International Scientific Conferences annually all over the world. OMICS International journals have over 15 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 50,000+ editorial board members that ensure a rapid, quality and quick review process. OMICS Group signed an agreement with more than 100 International Societies to make healthcare information Open Access. OMICS Group Conferences make the perfect platform for global networking as it brings together renowned speakers and scientists across the globe to a most exciting and memorable scientific event filled with much enlightening interactive sessions, world class exhibitions and poster presentations. Plants-derive compounds play crucial role in development of several anti-cancer drugs and they target proteins having significant regulatory effects on tumor cell cycle progress. Bioinformatics and cancer research overlap in many different areas in order to solve some problems in the field of treatment. In this study, the target and drug likeness of natural anticancer molecules are predicted by PASS software. Consequently, some new mechanisms of anticancer molecules have been introduced. They include Pseudobaptigenin with 0.702 PASS thresholds which revealed protein tyrosine kinase inhibitory. In addition, Kabophenol Aand Carasinol B with score 0.652 and 0.669 respectively exhibited topoisomerase I inhibitory effects. Moreover, Docetaxel, 7-xylosyl-10-deacetyl paclitaxel and Artemether by exhibiting the highest PASS score are the strongest anticancer agents in our research. It is notice worthy all of studied agents exhibited high drug-likeness score and it means that they can be applied as drug. Dr. Mehrdad Hashemi: Evaluating New Targets of Natural Anticancer Molecules through Bioinformatics Tools
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on March, 2021